Grand Rounds

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma

Donna Catamero, ANP-BC, OCN®, CCRC, Tiffany Richards, PhD, ANP-BC, AOCNP®, and Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN

From (1)Mount Sinai Health System, New York, New York; (2)The University of Texas MD Anderson Cancer Center, Houston, Texas; (3)Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

Authors’ disclosures of conflicts of interest are found at the end of this article.

Correspondence to: Donna Catamero, ANP-BC, OCN®, CCRC, 1468 Madison Avenue, New York, NY 10029. E-mail: donna.catamero@mssm.edu


J Adv Pract Oncol 2022;13(Suppl 4):31–43 | https://doi.org/10.6004/jadpro.2022.13.5.13 | © 2022 Harborside™


  

ABSTRACT

Significant strides have been made in the management of patients living with myeloma. However, patients with multiply relapsed or refractory multiple myeloma (MM) have a shorter overall survival; therefore, new treatments with novel mechanisms of action are needed in this patient population. Patients with relapsing disease require a full restaging workup, including whole body imaging to evaluate for extramedullary disease and lytic bone lesions, as well as bone marrow biopsy with fluorescence in situ hybridization to determine if the patient has any new chromosomal changes that are present. Therapies utilizing the patient’s immune cells, in particular T cells, provide a new option in relapsed/refractory myeloma. Treatment utilizing chimeric antigen receptor (CAR) T cells and/or bispecific antibody therapy provide excellent response rates. As such, advanced practitioners need to be aware of the potential toxicities associated with these newer treatments and how to manage them. This article will focus on the management of patients with relapsed and/or refractory disease who are undergoing treatment with either CAR T-cell therapy or bispecific T cell engager therapy.

Multiple Myeloma and Plasma Cell Disorders: Update on Diagnosis, Prognosis, Treatment, and Supportive Care
Introduction
A Focus on Newly Diagnosed Multiple Myeloma
A Focus on Relapsed Multiple Myeloma
A Focus on Special Populations in Relapsed Multiple Myeloma
A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
A Focus on Waldenström Macroglobulinemia and AL Amyloidosis




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.